استمتع بـUnlimited مع Magzter GOLD

استمتع بـUnlimited مع Magzter GOLD

احصل على وصول غير محدود إلى أكثر من 9000 مجلة وصحيفة وقصة مميزة مقابل

$149.99
 
$74.99/سنة

يحاول ذهب - حر

Why Singapore is Deep Tech Innovation Frontrunner

March 2024

|

BioSpectrum Asia

Move over Artificial Intelligence Al) and Machine Learning ML), there's a new technology on the block Deep Tech. This latest technology holds immense potential for the life sciences industry, and Singapore is leaving no stone unturned in becoming a deep tech hub. From strategic investments to collaborative initiatives and a supportive regulatory environment, read on to find out about the country's initiatives in becoming a deep tech superpower.

- Ayesha Siddiqui

Why Singapore is Deep Tech Innovation Frontrunner

Singapore has emerged as a significant player S in the global deep tech landscape. Over the past decade, the government has committed more than S$19 billion to advance research and development in deep tech, according to the Sparkmate report.

There are several initiatives aimed to strengthen the startup landscape in this sector. One key initiative driving Singapore's deep tech agenda is the Singapore Deep-Tech Alliance (SDTA), which facilitates partnerships and provides avenues for companies to create new startups, bring existing ones to market, find solutions to challenges, and access protected technologies. This initiative enhances collaboration and accelerates the growth of deep tech ventures within Singapore's ecosystem.

In addition, Singapore launched A*StartCentral (A*SC) in 2016, a first-of-its-kind open innovation platform by the Agency for Science Technology and Research (A*STAR). It aims to incubate and accelerate the growth of deep tech startups, and serves to bolster the startup ecosystem, including areas such as medtech and life sciences. Now it has over 150 deep tech startups.

"A*StartCentral (A*SC), a key player in Singapore's deep tech ecosystem, empowers earlystage startups in their entrepreneurial journey. By providing guidance and support, A*StartCentral enables startups to expand beyond Singapore and tap into global markets, fostering innovation and entrepreneurship on an international scale," said Emily Liew, Assistant Chief Executive Officer, Innovation & Enterprise Services, Enterprise Singapore.

A*SC builds upon the foundation of an open innovation community to foster crosspollination and interaction amongst researchers, corporates, startups, investors and entrepreneurs across diverse disciplines. A*SC will continue to inspire, innovate with, and empower researcherentrepreneurs in building successful, deep technology enabled ventures.

المزيد من القصص من BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

India signs MoU with Pfizer to strengthen healthcare innovation ecosystem

In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, Government of India, has signed a Memorandum of Understanding (MoU) with US-based Pfizer Limited.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

New Zealand to lead new gene therapy trial for muscular dystrophy

The first clinical trial of a new treatment for a rare form of muscular dystrophy is being led by New Zealand-based University of Auckland's Centre for Brain Research.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Scientists in Australia grow living skin in world-first

Australia's University of Queensland (UQ) researchers have been the first in the world to successfully grow fully functioning human skin in a laboratory.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

India joins Health AI Global Regulatory Network to strengthen oversight of AI in healthcare

HealthAI - The Global Agency for Responsible AI in Health, has welcomed India as a pioneer country joining the HealthAI Global Regulatory Network (GRN), a global network of health regulators dedicated to the safe and effective use of artificial intelligence (AI) in healthcare.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

TVM Capital Healthcare announces first closing of $150 M Southeast Asia Fund

Singapore-based TVM Capital Healthcare, a global private equity investor and operator specialised in healthcare growth capital across emerging markets, has announced the first closing of its $150 million TVM Healthcare Southeast Asia Fund (SEA Fund).

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

National Yang Ming Chiao Tung University, TSH Biopharm collaborate to foster pharma talent in Taiwan

Taiwan's National Yang Ming Chiao Tung University (NYCU) and TSH Biopharm have signed a five-year industry-academia collaboration Memorandum of Understanding (MOU).

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Fujifilm Biosciences introduces BalanCD HEK293 Perfusion A Medium

Fujifilm Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the life science market, has announced the commercial launch of BalanCD HEK293 Perfusion A.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Korea makes smart patch that can run tests using sweat instead of blood

A research team at Korea Advanced Institute of Science and Technology has developed a smart patch that can precisely observe internal changes through sweat when simply attached to the body.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

ADB approves $106.9 M to strengthen secondary healthcare services in Sri Lanka

The Asian Development Bank (ADB) has approved a $106.9 million financing package to strengthen Sri Lanka's secondary curative care services, improve communicable disease prevention and control, and enhance the healthcare sector's governance and management capacity.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Epigenic Therapeutics raises $60 M to accelerate clinical development of medicines

China-based startup Epigenic Therapeutics, a clinical-stage innovative drug development company, has announced the completion of a $60 million Series B round of financing led by Lapam Capital, with continued participation from existing investors Qiming Venture Partners and OrbiMed, and addition of new investors including IFSC and a renowned investment firm in the industry.

time to read

1 min

BioSpectrum Asia Oct 2025

Listen

Translate

Share

-
+

Change font size